Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pneumococcal Vaccination to Accelerate Immune Recovery in Sepsis Survivors

Trial Profile

Pneumococcal Vaccination to Accelerate Immune Recovery in Sepsis Survivors

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 18 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
  • Indications Pneumococcal infections
  • Focus Therapeutic Use
  • Acronyms VACIRiSS
  • Most Recent Events

    • 25 Mar 2019 Recruitment completion is expected on 31 Jan 2020, according to ISRCTN: Current Controlled Trials record.
    • 10 Dec 2018 The recruitment start date is 01/08/2018 and the recruitment end date of this study is 31/01/2020.
    • 20 Sep 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top